ACER THERAPEUTICS INC (ACER)

Company Profile

Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. The company is headquartered in Newton, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2006-09-01. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.

Company Info

ACER THERAPEUTICS INC

One Gateway Center (300 Washington St.), Suite 356

Newton MASSACHUSETTS 02458

P: 18449026100.0

CEO: Chris Schelling

Employees: 33

Website: https://acertx.com/